机构:[1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China[2]Department of Public Health, Chengdu Medical College, Chengdu, China[3]Department of Anesthesiology, Gulinxian People’s Hospital of Sichuan Province, Luzhou, China四川省人民医院[4]Department of Digestive Surgery, School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong[5]Department of Orthopedics, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China[6]Department of Art, Art College, Southwest Minzu University, Chengdu, China[7]Department of Neuroscience, Beijing Institute of Basic Medical Sciences, Beijing, China
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases the economic burden of the population. At present, the primary treatment of resectable pancreatic cancer is surgical resection, followed by chemotherapy with or without radiation. However, the recurrence rates remain high even after R0 resection. This treatment strategy does not distinguish undetected metastatic disease, and it is prone to postoperative complications. Neoadjuvant therapies, including neoadjuvant chemotherapy and radiotherapy, is being increasingly utilized in borderline resectable as well as resectable pancreatic cancer. This review summarized and discussed clinical trials of neoadjuvant therapy for pancreatic cancer, comparing resection rates, outcome measures, and adverse reactions between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy.
基金:
Chengdu Medical College
Foundation (CYZ19-33), Chengdu Science and Technology
Bureau focuses on research and development support plan
(2019-YF09-00097-SN), the popular scientific research project
of Sichuan Health Commission (20PJ171), and Sichuan
undergraduate innovation and startup program funding
support (S201913705080, S201913705130, S201913705059,
S202013705070, S202013705075, S202013705108), and Yunnan
education program (SYSX202036). National Natural Science
Foundation of China (82073833) and Southwest University for
Nationalities special fund for basic scientific research operations
of central universities (2021NYB08).
第一作者机构:[1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Yang Liqiong,Bai Yun,Li Qing,et al.Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.695645.
APA:
Yang, Liqiong,Bai, Yun,Li, Qing,Chen, Jie,Liu, Fangfang...&Xu, Fan.(2021).Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer.FRONTIERS IN ONCOLOGY,11,
MLA:
Yang, Liqiong,et al."Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer".FRONTIERS IN ONCOLOGY 11.(2021)